Penn Highlands DuBois Installs Masimo SedLine Brain Function Monitoring
Penn Highlands DuBois had been using Bispectral Index™ (BIS™) technology from Covidien.
"SedLine gives us more data on depths of anesthesia, and the Root technology platform allows us more additional Masimo MOC-9 technology options down the road to expand to fit our critical care monitoring needs," said
Root offers Masimo's SedLine® brain function monitoring, which provides four channels of EEG to help clinicians better understand the effects of anesthesia on the brain. SedLine measures the effects of anesthesia and sedation by monitoring both sides of the brain's electrical activity. As such, SedLine provides a wealth of EEG-based data, which can help clinicians monitor anesthesia.
"Time matters, of course, when it comes to clinical decisions," DeVallance added. "But SedLine also offers us cost savings. We're not over-sedating patients, so we're not wasting (anesthesia) gases."
"We are proud that after careful consideration, Penn Highlands DuBois selected
About Penn Highlands DuBois
Penn Highlands DuBois offers residents of west central
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com. @masimoinnovates
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that SedLine helps anesthesia providers deliver the desired level of targeted sedation throughout all phases of anesthesia; risks related to our assumptions of the repeatability of clinical results obtained; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.